NCT05612178View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 26, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
HIV-1
Interventions
BIOLOGICAL

3BNC117-LS

Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.

BIOLOGICAL

10-1074-LS

Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10- 1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.

OTHER

Sterile Saline

Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks, 20 and 40.

Trial Locations (2)

10065

RECRUITING

The Rockefeller University, New York

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH